Skip to main content
. Author manuscript; available in PMC: 2016 Jun 8.
Published in final edited form as: Cancer Cell. 2015 Jun 8;27(6):797–808. doi: 10.1016/j.ccell.2015.05.005

Figure 7. Activation of YAP1 in prostate epithelium in vivo is sufficient for the developmen of age-related prostate tumors.

Figure 7

(A) Model showing the development of prostate epithelium-specific YAP1-GOF mice.

(B) Western blot (WB) analysis of YAP1, TAZ and [.beta]-actin expression in total proteins extracted from ventral prostates of 20 month-old control (WT) and YAP1-GOF mice.

(C-I) Hematoxylin and Eosin (H&E, I) and immunohistochemical (C-H) staining of large prostatic sarcomatoid carcinoma in 14 month-old YAP1-GOF male. Staining with anti-androgen receptor (AR), anti-E-cadherin (E-cad), anti-smooth muscle actin (SMA), anti-YAP1 (YAP), anti-pancytokeratin (cytoker) and anti-Vimentin (viment) antibodies. Bar in I represents 1.4 mm in I, 0.4 mm in C-H, 40 μm in insets.

(J) Prostate tumor incidence and tumor types in YAP1-GOF and control littermate mice. YAP1-GOF-triple mutant Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+, Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+, Tg(Pbsn-cre)4Prb/0. Control - double mutant Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+, Tg(Pbsn-cre)4Prb/0. Numbers denote mice with indicated tumors relative to the number of mice analyzed. The prostate glands were analyzed in mice euthanized at morbidity. The Dox exposure was started at 3 months of age and varied between 12 and 16 months. Two-tailed Fisher's exact test.

(K) Model showing the role of ERG and YAP1 in prostate cancer development. See also Figure S5, Tables S6-S8.